School-based hepatitis B vaccination programme and adolescent multiple sclerosis

Lancet

Volumn 355, Issue 9203, 2000, Pages 549-550

  Sadovnick, A Dessa ^a   Scheifele, David W ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ADOLESCENT; ARTICLE; CANADA; COMPARATIVE STUDY; CONTROLLED STUDY; DEMYELINATING DISEASE; ENCEPHALOMYELITIS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 0034639744     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)02991-8     Document Type: Article

References (5)

1. Walsh E. A shadow falls on hepatitis B vaccination effort. Science. 281:1998;630-631.
2. Kane M.A. Commentary: public perception and the safety of immunization. Vaccine. 16:1998;S73-S75.
3. Pless, R. Surveillance section, vaccine-associated adverse events, Laboratory Centre for Disease Control, Health Canada. Hep B/MS/QA, 23/04/98.
4. Halsey N.A., Duclos P., Van Damme P., Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases. Pediatr Infect Dis. 16:1999;23-24.
5. Kastrukoff L.F., Rice G.P.A. Virology. Paty D.W., Ebers G.C. Multiple Sclerosis. 1997;370-402 F A Davis Company, Philadelphia.